600276 Jiangsu Hengrui Pharmaceuticals Co.,Ltd.
Closed 04-03 15:00:00
56.38
-0.99
-1.73%
High56.99Low56.10Vol45.49M
Open56.98D1 Closing57.37Amplitude1.55%
Mkt Cap374.19BTradable Cap359.65BTotal Shares6.64B
T/O2.57BT/O Rate0.71%Tradable Shares6.38B
P/B6.11ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Morgan Stanley Assigns "Overweight" Rating to Hengrui Pharma with HK$92 Price Target
Stock News  ·  04-01
Morgan Stanley Assigns "Overweight" Rating to Hengrui Pharma with HK$92 Price Target
BRIEF-Hengrui Pharma And Braveheart Bio Announce Positive Phase 2 Results With Hrs/BHB-1893 In Obstructive Hypertrophic Cardiomyopathy
Reuters  ·  03-30
BRIEF-Hengrui Pharma And Braveheart Bio Announce Positive Phase 2 Results With Hrs/BHB-1893 In Obstructive Hypertrophic Cardiomyopathy
Hengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results With Hrs/Bhb-1893 in Obstructive Hypertrophic Cardiomyopathy
THOMSON REUTERS  ·  03-30
Hengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results With Hrs/Bhb-1893 in Obstructive Hypertrophic Cardiomyopathy
New Appointments for Li Yanhong and Sun Piaoyang
Deep News  ·  03-27
New Appointments for Li Yanhong and Sun Piaoyang
SIMCERE PHARMA Shares Surge Nearly 8% in Morning Session Following Appointment of Former HENGRUI PHARMA Chairman as CEO
Stock News  ·  03-27
SIMCERE PHARMA Shares Surge Nearly 8% in Morning Session Following Appointment of Former HENGRUI PHARMA Chairman as CEO
Jiangsu Hengrui gains China clinical trial clearance for HRS9531 injection; R&D spending grows to CNY 632 million
Reuters  ·  03-26
Jiangsu Hengrui gains China clinical trial clearance for HRS9531 injection; R&D spending grows to CNY 632 million
Hengrui Pharma's HRS9531 Injection Receives Clinical Trial Approval
Stock News  ·  03-26
Hengrui Pharma's HRS9531 Injection Receives Clinical Trial Approval
Jiangsu Hengrui Pharmaceuticals' Profit, Revenue Climb in 2025
MT Newswires Live  ·  03-26
Jiangsu Hengrui Pharmaceuticals' Profit, Revenue Climb in 2025
Hengrui Pharma Announces Strong 2025 Annual Results
THOMSON REUTERS  ·  03-26
Hengrui Pharma Announces Strong 2025 Annual Results
Jiangsu Hengrui Medicine FY2025 final dividend is proposed at RMB 2 per 10 shares; shareholder approval is set for April 16, 2026
Reuters  ·  03-26
Jiangsu Hengrui Medicine FY2025 final dividend is proposed at RMB 2 per 10 shares; shareholder approval is set for April 16, 2026
Jiangsu Hengrui Medicine FY2025 publishes ESG report; MSCI ESG rating climbs to AA
Reuters  ·  03-26
Jiangsu Hengrui Medicine FY2025 publishes ESG report; MSCI ESG rating climbs to AA
BRIEF-Jiangsu Hengrui Pharmaceuticals Entered Into Capital Increase Agreement With Hengrui Group, Others
Reuters  ·  03-25
BRIEF-Jiangsu Hengrui Pharmaceuticals Entered Into Capital Increase Agreement With Hengrui Group, Others
HENGRUI PHARMA to Inject 285 Million Yuan into Shanghai Ruihongdi
Stock News  ·  03-25
HENGRUI PHARMA to Inject 285 Million Yuan into Shanghai Ruihongdi
SIMCERE PHARMA Announces Dr. Zhou Yunshu as New CEO
Stock News  ·  03-25
SIMCERE PHARMA Announces Dr. Zhou Yunshu as New CEO
Jiangsu Hengrui Pharmaceuticals - Entered Capital Increase Agreement With Hengrui Group, Shengdi Biomedical Fund, and Others
THOMSON REUTERS  ·  03-25
Jiangsu Hengrui Pharmaceuticals - Entered Capital Increase Agreement With Hengrui Group, Shengdi Biomedical Fund, and Others
Jiangsu Hengrui Pharmaceuticals - Co, Others to Contribute in Aggregate RMB750.0 Mln
THOMSON REUTERS  ·  03-25
Jiangsu Hengrui Pharmaceuticals - Co, Others to Contribute in Aggregate RMB750.0 Mln
Hengrui Pharma FY2025; innovation drug revenue rises to CNY 16.3 billion; net profit grows to CNY 7.7 billion
Reuters  ·  03-25
Hengrui Pharma FY2025; innovation drug revenue rises to CNY 16.3 billion; net profit grows to CNY 7.7 billion
Jiangsu Hengrui Pharmaceuticals 2025 Net Profit up 21.7%
THOMSON REUTERS  ·  03-25
Jiangsu Hengrui Pharmaceuticals 2025 Net Profit up 21.7%
Chinese drugmaker Hengrui's quarterly profit misses forecasts amid generic drug business squeeze
Reuters  ·  03-25
Chinese drugmaker Hengrui's quarterly profit misses forecasts amid generic drug business squeeze
BRIEF-Jiangsu Hengrui Pharmaceuticals Says NMPA Approval Granted For Trastuzumab Rezetecan For Injection
Reuters  ·  03-20
BRIEF-Jiangsu Hengrui Pharmaceuticals Says NMPA Approval Granted For Trastuzumab Rezetecan For Injection

Introduction

Company Name.
江苏恒瑞医药股份有限公司
Industry:
医药制造业
Listing Date:
2000-10-18
Main Business:
　　江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是马来酸吡咯替尼片、注射用卡瑞利珠单抗、瑞维鲁胺片、海曲泊帕乙醇酰胺片、羟乙磺酸达尔西利片、碘佛醇注射液。自2019年起，公司连续七年跻身美国《制药经理人》(PharmExec)杂志评选的全球制药企业50强榜单。
Issue price:
11.98